COMBINATION CHEMOTHERAPY WITH ETOPOSIDE, CISPLATIN, AND DOXORUBICIN IN MIXED MULLERIAN TUMORS OF THE ADNEXA

Eleven patients with ovarian (9) or fallopian tube (2) mixed mullerian tumors who underwent primary surgery at Yale New Haven Medical Center between 1986 and 1994 were treated with etoposide, cisplatin, and dox orubicin. Responses were observed in three (60%) of five evaluable pat ients with two complete (40%) and one partial (20%) response. Median s urvival time was 17 months with an estimated 3-year survival of 18%. S urvival may have been improved with earlier stage disease, but surviva l was not significantly improved with optimal surgical cytoreduction i n patients with advanced disease. Four patients required dose reductio ns for myelosuppression and there was one treatment related death. Tox icity was comparable to other combination chemotherapy regimens. EPA h as modest therapeutic activity in ovarian and fallopian tube MMT. (C) 1996 Academic Press, Inc.